The current stock price for Humacyte Inc. (HUMA) is $3.61. The stock experienced a significant increase during the last trading session, reaching $3.99 after opening at $3.98. It dipped to a low of $3.52 before ultimately closing at $3.92.
In terms of market performance, Humacyte Inc. had a somewhat inconsistent run in. The highest value for the stock in the past year was $6.38 on 06/03/22, while the lowest value was $1.96 on 12/30/22.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
52-week price history of HUMA Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. Humacyte Inc.’s current trading price is -43.42% away from its 52-week high, while its distance from the 52-week low is 84.18%. The stock’s price range during this period has fluctuated between $1.96 and $6.38. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 0.75 million for the day, which was evidently higher than the average daily volume of 0.26 million over the last three months.
Financial Performance and Market Capitalization
Humacyte Inc. (HUMA) has experienced a quarterly rise of 24.05% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 379.30M and boasts a workforce of 164 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.18, with a change in price of +1.50. Similarly, Humacyte Inc. recorded 251,424 in trading volume during the last 100 days, posting a change of +71.09%.
HUMA Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HUMA stands at 0.61. Similarly, the long-term debt-to-equity ratio is also 0.42.
HUMA Stock Stochastic Average
Humacyte Inc.’s raw stochastic average for the past 50 days is currently at 32.54%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 20.40%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 30.00% and 36.93%, respectively.
HUMA Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant gain of 71.09% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 10.40%. Over the past 30 days, the price of HUMA has fallen by 8.73%. And in the last five days, it has fallen by -14.25%.
